Kisunla access guide: country options for cross-border named-patient access

Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.

About Kisunla

Kisunla (donanemab-azbt) is a anti-amyloid beta monoclonal antibody (N3pG-targeted) approved by the US Food and Drug Administration for early symptomatic Alzheimer disease (mild cognitive impairment and mild dementia stage) with confirmed amyloid pathology. The current FDA label is available at accessdata.fda.gov. Kisunla is marketed by Eli Lilly. Reserve Meds coordinates US-sourced cross-border access to Kisunla under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Kisunla in each jurisdiction Reserve Meds has authored.

Kisunla country-specific access guides

Reserve Meds has published 11 country-specific access guides for Kisunla. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.

Arabic-language guides are available for: Abu Dhabi, Bahrain, Dubai, Kuwait, Qatar, Saudi Arabia, UAE. Switch languages via the page footer or the URL prefix /ar/.

Other countries not yet authored

Reserve Meds has authored country-specific access guides for Kisunla in the 11 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Kisunla. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.

Request a Kisunla access scope for your country

Related Reserve Meds resources

• Access pathways index (named-patient, personal-import, hospital-exemption, and equivalent frameworks by country)
• Conditions index (the indication families Reserve Meds coordinates around)
• Drug catalog (all FDA-labeled medicines in the Reserve Meds coordination scope)
• All country-specific access guides
• How Reserve Meds coordinates a cross-border case
• Trust, compliance, and editorial review

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.

Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.